RXRX Stock Plunges 9.98% as AI Drug Pipeline Stumbles, Falls to 386th in U.S. Dollar Volume

On October 10, 2025, Recursion Pharmaceuticals (RXRX) reported a 9.98% decline in its stock price, with a trading volume of $330 million, ranking 386th in dollar volume among U.S. equities. The sharp drop followed a lack of significant therapeutic advancements in its AI-driven drug discovery pipeline during the quarter, alongside broader market skepticism about the commercial viability of its platform in the competitive biotech sector.

Analysts noted that the company's recent quarterly earnings call highlighted delays in clinical trial timelines for its lead candidates, including RYB302 for retinal degeneration. While the firm reiterated its long-term vision for AI integration in preclinical research, short-term investor sentiment remained cautious, with many funds reducing exposure to high-growth biotech names amid a sector-wide earnings downturn.

Back-testing parameters for the stock’s performance require clarification on key variables: the benchmark universe (e.g., S&P 500 constituents vs. broader U.S. equities), weighting methodology for a 500-stock portfolio, and execution assumptions such as one-day holding periods. Transaction cost modeling and liquidity adjustments also remain open questions. Implementation options include constructing a synthetic index or using an ETF proxy like RSP, depending on the desired level of precision in simulating daily rebalancing strategies.